Developer docs
API playgroundTry for free, no card

Search company profiles

Xediton Pharmaceuticals

Full company profile

uuid0007ewy

Namestring
Xediton Pharmaceuticals
Legal namestring
Xediton Pharmaceuticals Inc.
Websiteurl
xediton.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Xediton Pharmaceuticals Inc. is a privately held Canadian specialty pharmaceutical company headquartered in Oakville, Ontario, founded in 2007. The company operates an asset-light business model focused on licensing, commercializing, and managing the lifecycle of branded pharmaceutical products in the Canadian market, without engaging in proprietary drug discovery or development. Its portfolio spans 31 prescription medications across multiple therapeutic areas — including Oncology, Anti-Infectives, Cardiovascular, Gastroenterology, Pain, CNS, Ophthalmology, Renal, and Weight Management — sourced through long-term partnerships with global pharmaceutical companies such as Cheplapharm Arzneimittel, Sebela Pharmaceuticals, Grunenthal Group, Melinta Therapeutics, and Quantum Genomics. The company has stated a focus on specialty care, matured/established brands, niche products, and both patented and non-patented products.

The company generates revenue primarily through product sales of prescription medications, medical devices, and over-the-counter (OTC) products in Canada, distributed through all major Canadian pharmaceutical wholesalers, hospital buying groups, and a territory-based direct sales force. Xediton's go-to-market combines a sales-led motion for healthcare professional engagement with a channel-partner strategy for international licensors seeking Canadian market entry. Value-added services include Health Canada regulatory submissions, market access and reimbursement management, sales and marketing execution, and full lifecycle management of licensed products. Pricing is not publicly disclosed, with customers directed to phone/email customer service for quotes.

In February 2025, Xediton completed the acquisition of Valeo Pharma Inc. through a court-approved share purchase agreement under the Companies' Creditors Arrangement Act (CCAA), adding wholly-owned subsidiaries Valeo Pharma Corp. and VPI Pharmaceuticals Inc. and expanding the portfolio into Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products. The company remains privately held with no public funding rounds, venture capital investment, or revenue disclosures documented in the available materials; George Gafrey serves as President and CEO.

Short descriptiontext

Xediton Pharmaceuticals is a privately held Canadian specialty pharmaceutical company that licenses, commercializes, and manages branded prescription drugs, medical devices, and OTC products across multiple therapeutic areas for the Canadian market through partnerships with global pharmaceutical firms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOakville, Canada
HQ citystring
Oakville
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, prescription medications, drug commercialization, pharmaceutical licensing, medical devices
Industry1 code
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Xediton generates revenue through the sale of prescription medications, medical devices, and over-the-counter (OTC) products in the Canadian market. Products include specialty care medications, matured/established brands, niche products, and both patented and non-patented products.

xediton.com
2Licensing and Commercialization Rights
TypeLicensing Royalties
Description

Xediton obtains exclusive rights to commercialize products in Canada through licensing agreements with international pharmaceutical partners. The company is responsible for registration and commercialization of licensed products in the Canadian market, including regulatory submissions to Health Canada.

xediton.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Marketing or Sales, Operations, Supply Chain, Technology or R&D, Infrastructure
Pricing details1 tier
1Pricing available upon inquiry through customer service
ModelOtherBilling cadencePay-as-you-go
Notes

Xediton does not publicly disclose product pricing. Customers must contact customer service at customerservice@xediton.com or call 1-888-933-4866 for pricing information.

xediton.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Xediton licenses, acquires, and commercializes specialty pharmaceutical products—including prescription medications, medical devices, and OTC products—for the Canadian market. The company handles regulatory submissions to Health Canada, market access, and sales through wholesalers, hospitals, and a territory-based sales force, partnering with global pharmaceutical companies to bring established and innovative drugs to Canadian patients.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Xediton Pharmaceuticals is a privately held Canadian specialty pharmaceutical company founded in 2007, headquartered in Oakville, Ontario. The company operates through licensing and acquisition of pharmaceutical products for the Canadian market. The portfolio consists of 31 prescription medications spanning multiple therapeutic areas including Oncology (Anandron, Vepesid, Vesanoid), Anti-Infectives (Cytovene, Fungizone, Valcyte), Cardiovascular (Inhibace, Inhibace Plus, Visken, Viskazide), Gastroenterology (Losec, Vimovo), Neurology/Psychiatry (Rivotril), Immunology/Rheumatology (Ridaura), Urology/Endocrinology (Suprefact), Ophthalmology (Visudyne), and Weight Management (Xenical). The company also commercializes products under licensing agreements with partners such as Melinta Therapeutics (BAXDELA, KIMYRSA, ORBACTIV, VABOMERE). Following the February 2025 acquisition of Valeo Pharma Inc., the company expanded its portfolio to include products in Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products.

Product and service33 records
1Anandron 50mg Tablets
CategoryPrescription pharmaceutical (Oncology)
Description

Nilutamide nonsteroidal antiandrogen medication used for metastatic prostatic carcinoma; dispensed via Canadian wholesalers and hospitals.

2Cytovene 500mg Injection
CategoryPrescription pharmaceutical (Anti-Infectives)
Description

Ganciclovir antiviral agent for treatment of cytomegalovirus (CMV) retinitis; sold to Canadian hospitals and wholesalers.

3Fungizone 50mg Vial
CategoryPrescription pharmaceutical (Anti-Infectives)
Description

Amphotericin B antifungal agent for disseminated mycotic infections; distributed through Canadian wholesalers.

4Inhibace 5mg Tablets
CategoryPrescription pharmaceutical (Cardiovascular)
Description

Cilazapril angiotensin-converting enzyme inhibitor used for hypertension and congestive heart failure.

5Inhibace Plus 5/12.5mg Tablets
CategoryPrescription pharmaceutical (Cardiovascular)
Description

Combination of cilazapril and hydrochlorothiazide (ACE inhibitor/diuretic) used for hypertension.

6Losec 20mg Capsules
CategoryPrescription pharmaceutical (Gastroenterology)
Description

Omeprazole proton pump inhibitor (PPI) for peptic ulcer disease and acid reflux.

7Losec 20mg MUPS Tablets
CategoryPrescription pharmaceutical (Gastroenterology)
Description

Omeprazole proton pump inhibitor (PPI) in MUPS formulation for peptic ulcer disease and acid reflux.

8One Alpha 0.25mcg Capsules
CategoryPrescription pharmaceutical (Renal/Endocrinology)
Description

Alfacalcidol vitamin D analogue for management of hypocalcemia, secondary hyperparathyroidism and osteodystrophy.

9One Alpha 1mcg Capsules
CategoryPrescription pharmaceutical (Renal/Endocrinology)
Description

Alfacalcidol vitamin D analogue (1mcg strength) for management of hypocalcemia, secondary hyperparathyroidism and osteodystrophy.

10One Alpha 2mcg IV 10X0.5ml Ampoules
CategoryPrescription pharmaceutical (Renal/Endocrinology)
Description

Intravenous alfacalcidol vitamin D analogue for management of hypocalcemia, secondary hyperparathyroidism and osteodystrophy.

11One Alpha 2mcg IV 10X1ml Ampoules
CategoryPrescription pharmaceutical (Renal/Endocrinology)
Description

Intravenous alfacalcidol vitamin D analogue (higher volume ampoule) for management of hypocalcemia, secondary hyperparathyroidism and osteodystrophy.

12One Alpha 2mcg/mL 20ml Drops
CategoryPrescription pharmaceutical (Renal/Endocrinology)
Description

Oral drops formulation of alfacalcidol vitamin D analogue for hypocalcemia, secondary hyperparathyroidism and osteodystrophy.

13Ridaura 3mg Capsules
CategoryPrescription pharmaceutical (Immunology/Rheumatology)
Description

Auranofin antirheumatic agent for active rheumatoid arthritis.

14Rivotril 0.5mg Tablets
CategoryPrescription pharmaceutical (Neurology/CNS)
Description

Clonazepam anticonvulsant for myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut Syndrome).

15Rivotril 2mg Tablets
CategoryPrescription pharmaceutical (Neurology/CNS)
Description

Clonazepam anticonvulsant (higher strength) for myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut Syndrome).

16Rythmodan 100mg Capsules
CategoryPrescription pharmaceutical (Cardiovascular)
Description

Disopyramide antiarrhythmic agent for documented life-threatening ventricular arrhythmias.

17Suprefact 6.3mg Depot
CategoryPrescription pharmaceutical (Urology/Oncology)
Description

Buserelin (Buserelin Acetate) LHRH analogue for hormone-dependent advanced carcinoma of the prostate gland (Stage D).

18Suprefact 9.45mg Depot
CategoryPrescription pharmaceutical (Urology/Oncology)
Description

Buserelin (Buserelin Acetate) LHRH analogue (higher dose) for hormone-dependent advanced carcinoma of the prostate gland (Stage D).

19Suprefact Injection 1mg/ml
CategoryPrescription pharmaceutical (Urology/Oncology)
Description

Buserelin (Buserelin Acetate) LHRH analogue injectable solution for hormone-dependent advanced prostate carcinoma.

20Valcyte 450mg Tablets
CategoryPrescription pharmaceutical (Anti-Infectives/Ophthalmology)
Description

Valganciclovir antiviral agent for cytomegalovirus (CMV) retinitis.

21Valcyte 50mg/ml
CategoryPrescription pharmaceutical (Anti-Infectives/Ophthalmology)
Description

Valganciclovir oral solution antiviral agent for cytomegalovirus (CMV) retinitis.

22Vepesid 50mg Capsules
CategoryPrescription pharmaceutical (Oncology)
Description

Etoposide antineoplastic agent for small and non-small cell carcinoma of the lung, malignant lymphoma, and testicular malignancies.

23Vesanoid 10mg Capsules
CategoryPrescription pharmaceutical (Oncology)
Description

Tretinoin differentiation inducing agent for acute promyelocytic leukemia.

24Vimovo 375/20mg Tablets
CategoryPrescription pharmaceutical (Pain/Rheumatology)
Description

Combination of naproxen and esomeprazole NSAID with proton pump inhibitor for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

25Vimovo 500/20mg Tablets
CategoryPrescription pharmaceutical (Pain/Rheumatology)
Description

Higher strength combination of naproxen and esomeprazole NSAID with proton pump inhibitor for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

26Viskazide 10/50 Tablets
CategoryPrescription pharmaceutical (Cardiovascular)
Description

Pindolol/hydrochlorothiazide antihypertensive combination agent for hypertension.

27Viskazide 1025 Tablets
CategoryPrescription pharmaceutical (Cardiovascular)
Description

Pindolol/hydrochlorothiazide antihypertensive combination agent (different ratio) for hypertension.

28Visken 10mg Tablets
CategoryPrescription pharmaceutical (Cardiovascular)
Description

Pindolol antihypertensive and antianginal agent for hypertension and angina pectoris.

29Visken 5mg Tablets
CategoryPrescription pharmaceutical (Cardiovascular)
Description

Pindolol antihypertensive and antianginal agent (lower strength) for hypertension and angina pectoris.

30Visudyne 15mg Injection
CategoryPrescription pharmaceutical (Ophthalmology)
Description

Verteporfin photosensitizing agent for classic subfoveal choroidal neovascularization in patients with age-related macular degeneration, pathologic myopia, and presumed ocular histoplasmosis.

31Xenical 120mg Capsules
CategoryPrescription pharmaceutical (Weight Management)
Description

Orlistat anti-obesity agent and gastrointestinal lipase inhibitor for obesity management, weight loss and weight maintenance.

32Melinta Therapeutics Anti-Infective Portfolio (BAXDELA, KIMYRSA, ORBACTIV, VABOMERE)
CategoryPrescription pharmaceutical (Anti-Infectives)
Description

In-licensed portfolio of four novel anti-infective prescription products from Melinta Therapeutics (BAXDELA, KIMYRSA, ORBACTIV, VABOMERE) registered and commercialized by Xediton in Canada for pathogens on Canada's Pathogens of Interest List.

33Valeo Pharma-Acquired Specialty Pharmaceutical Portfolio
CategoryPrescription pharmaceutical (Respiratory/Allergy, Ophthalmology, Hospital Specialty)
Description

Specialty pharmaceutical portfolio in Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products, retained through the February 2025 acquisition of Valeo Pharma Inc. (including subsidiaries Valeo Pharma Corp. and VPI Pharmaceuticals Inc.).

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-04
Description

Xediton completed a share purchase agreement to acquire 100% of Valeo Pharma Inc., which was under proceedings under the Companies' Creditors Arrangement Act (CCAA). The transaction was approved by the Quebec Superior Court on February 4, 2025. Xediton retained Valeo's existing licenses, operating permits, supply agreements, product listing agreements, intellectual property, and ownership of Valeo's subsidiaries (Valeo Pharma Corp. and VPI Pharmaceuticals Inc.).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-15
Description

Exclusive commercialization and licensing agreement for four novel anti-infective products: BAXDELA (delafloxacin), KIMYRSA (oritavancin), ORBACTIV (oritavancin), and VABOMERE (meropenem and vaborbactam). Xediton is responsible for registration and commercialization of these products in Canada. These products have been approved by the US FDA and may be eligible for Priority Review by Health Canada.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-term international partnership for bringing pharmaceutical products to the Canadian market. Cheplapharm is a German pharmaceutical company with a focus on established medicines.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership with Sebela Pharmaceuticals for product licensing and commercialization in Canada. Sebela is a global pharmaceutical company.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

International partnership with Grunenthal Group, a German pharmaceutical company specializing in pain management and other therapeutic areas, to bring products to the Canadian market.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership with Quantum Genomics, a biopharmaceutical company focused on cardiovascular and neurological diseases, for potential product introduction to Canadian market.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian specialty pharma focused on women's health, oncology, and rare diseases; comparable in-licensing and commercialization profile within the Canadian market.

TypeOthers
Description

U.S. anti-infectives company that licensed four products (BAXDELA, KIMYRSA, ORBACTIV, VABOMERE) to Xediton for Canada; a direct partner and therefore a closely adjacent rather than competing entity.

TypeBroad incumbent
Description

Canada's largest generic pharmaceutical manufacturer and distributor; competes with Xediton for the same Canadian wholesale channel and overlapping prescriber base, though Apotex is a manufacturer rather than a pure commercialization partner.

TypeDirect peer
Description

Canadian specialty pharma that licenses, acquires, and commercializes niche and mature products across multiple therapeutic categories in Canada, sharing Xediton's lean commercialization approach and geographic concentration.

TypeDirect peer
Description

Montreal-based Canadian specialty pharmaceutical company with an in-licensing and commercialization model very similar to Xediton's, focused on acquiring and commercializing innovative and established products in Canada and select emerging markets.

TypeDirect peer
Description

Canadian specialty pharmaceutical company focused on acquiring and commercializing late-stage products, including established brands, in Canada — a direct analogue in both therapeutic strategy and Canadian-only footprint.

TypeDirect peer
Description

Canadian specialty pharma that in-licenses and commercializes branded prescription, OTC, and diagnostic products in Canada — a closely analogous in-licensing commercialization peer to Xediton.

8Bausch Health Companies
TypeBroad incumbent
Description

Large Canadian-headquartered specialty pharma with a broad therapeutic-area portfolio and established Canadian commercial infrastructure; overlaps with Xediton on the specialty/mature-brand strategy but at vastly greater scale.

TypeDirect peer
Description

Canadian specialty pharma (acquired by Endo) historically built on in-licensing niche and established products for the Canadian market — directly comparable business model to Xediton's pre-Valeo operations.

TypeOthers
Description

German specialty pharma specializing in established-brand lifecycles and a long-term Xediton partner; a useful upstream comparator for the mature-brand commercialization model Xediton runs in Canada.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xediton Pharmaceuticals

Specialty Pharmaceuticalsxediton.com

Xediton Pharmaceuticals is a privately held Canadian specialty pharmaceutical company that licenses, commercializes, and manages branded prescription drugs, medical devices, and OTC products across multiple therapeutic areas for the Canadian market through partnerships with global pharmaceutical firms.

What Xediton Pharmaceuticals does

Xediton Pharmaceuticals Inc. is a privately held Canadian specialty pharmaceutical company headquartered in Oakville, Ontario, founded in 2007. The company operates an asset-light business model focused on licensing, commercializing, and managing the lifecycle of branded pharmaceutical products in the Canadian market, without engaging in proprietary drug discovery or development. Its portfolio spans 31 prescription medications across multiple therapeutic areas — including Oncology, Anti-Infectives, Cardiovascular, Gastroenterology, Pain, CNS, Ophthalmology, Renal, and Weight Management — sourced through long-term partnerships with global pharmaceutical companies such as Cheplapharm Arzneimittel, Sebela Pharmaceuticals, Grunenthal Group, Melinta Therapeutics, and Quantum Genomics. The company has stated a focus on specialty care, matured/established brands, niche products, and both patented and non-patented products.

The company generates revenue primarily through product sales of prescription medications, medical devices, and over-the-counter (OTC) products in Canada, distributed through all major Canadian pharmaceutical wholesalers, hospital buying groups, and a territory-based direct sales force. Xediton's go-to-market combines a sales-led motion for healthcare professional engagement with a channel-partner strategy for international licensors seeking Canadian market entry. Value-added services include Health Canada regulatory submissions, market access and reimbursement management, sales and marketing execution, and full lifecycle management of licensed products. Pricing is not publicly disclosed, with customers directed to phone/email customer service for quotes.

In February 2025, Xediton completed the acquisition of Valeo Pharma Inc. through a court-approved share purchase agreement under the Companies' Creditors Arrangement Act (CCAA), adding wholly-owned subsidiaries Valeo Pharma Corp. and VPI Pharmaceuticals Inc. and expanding the portfolio into Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products. The company remains privately held with no public funding rounds, venture capital investment, or revenue disclosures documented in the available materials; George Gafrey serves as President and CEO.

Xediton Pharmaceuticals firmographics

Firmographics
Name
Xediton Pharmaceuticals
Legal name
Xediton Pharmaceuticals Inc.
Website
https://xediton.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
Xediton Pharmaceuticals is a privately held Canadian specialty pharmaceutical company that licenses, commercializes, and manages branded prescription drugs, medical devices, and OTC products across multiple therapeutic areas for the Canadian market through partnerships with global pharmaceutical firms.
Ownership category
akta.pro rank

Xediton Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing

Keywords

  • Specialty pharmaceuticals
  • Prescription medications
  • Drug commercialization
  • Pharmaceutical licensing
  • Medical devices

Where Xediton Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Oakville
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Xediton Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Xediton generates revenue through the sale of prescription medications, medical devices, and over-the-counter (OTC) products in the Canadian market. Products include specialty care medications, matured/established brands, niche products, and both patented and non-patented products.
  2. Licensing and Commercialization Rights: Xediton obtains exclusive rights to commercialize products in Canada through licensing agreements with international pharmaceutical partners. The company is responsible for registration and commercialization of licensed products in the Canadian market, including regulatory submissions to Health Canada.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPricing available upon inquiry through customer service

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Xediton Pharmaceuticals product offering

Product offering

Core offering

Xediton licenses, acquires, and commercializes specialty pharmaceutical products—including prescription medications, medical devices, and OTC products—for the Canadian market. The company handles regulatory submissions to Health Canada, market access, and sales through wholesalers, hospitals, and a territory-based sales force, partnering with global pharmaceutical companies to bring established and innovative drugs to Canadian patients.

Product overview

Xediton Pharmaceuticals is a privately held Canadian specialty pharmaceutical company founded in 2007, headquartered in Oakville, Ontario. The company operates through licensing and acquisition of pharmaceutical products for the Canadian market. The portfolio consists of 31 prescription medications spanning multiple therapeutic areas including Oncology (Anandron, Vepesid, Vesanoid), Anti-Infectives (Cytovene, Fungizone, Valcyte), Cardiovascular (Inhibace, Inhibace Plus, Visken, Viskazide), Gastroenterology (Losec, Vimovo), Neurology/Psychiatry (Rivotril), Immunology/Rheumatology (Ridaura), Urology/Endocrinology (Suprefact), Ophthalmology (Visudyne), and Weight Management (Xenical). The company also commercializes products under licensing agreements with partners such as Melinta Therapeutics (BAXDELA, KIMYRSA, ORBACTIV, VABOMERE). Following the February 2025 acquisition of Valeo Pharma Inc., the company expanded its portfolio to include products in Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products.

Differentiator

Problem solved

Functional benefit

Products and services

  • Anandron 50mg Tablets Nilutamide nonsteroidal antiandrogen medication used for metastatic prostatic carcinoma; dispensed via Canadian wholesalers and hospitals.
  • Cytovene 500mg Injection Ganciclovir antiviral agent for treatment of cytomegalovirus (CMV) retinitis; sold to Canadian hospitals and wholesalers.
  • Fungizone 50mg Vial Amphotericin B antifungal agent for disseminated mycotic infections; distributed through Canadian wholesalers.
  • Inhibace 5mg Tablets Cilazapril angiotensin-converting enzyme inhibitor used for hypertension and congestive heart failure.
  • Inhibace Plus 5/12.5mg Tablets Combination of cilazapril and hydrochlorothiazide (ACE inhibitor/diuretic) used for hypertension.
  • Losec 20mg Capsules Omeprazole proton pump inhibitor (PPI) for peptic ulcer disease and acid reflux.
  • Losec 20mg MUPS Tablets Omeprazole proton pump inhibitor (PPI) in MUPS formulation for peptic ulcer disease and acid reflux.
  • One Alpha 0.25mcg Capsules Alfacalcidol vitamin D analogue for management of hypocalcemia, secondary hyperparathyroidism and osteodystrophy.
  • One Alpha 1mcg Capsules Alfacalcidol vitamin D analogue (1mcg strength) for management of hypocalcemia, secondary hyperparathyroidism and osteodystrophy.
  • One Alpha 2mcg IV 10X0.5ml Ampoules Intravenous alfacalcidol vitamin D analogue for management of hypocalcemia, secondary hyperparathyroidism and osteodystrophy.
  • One Alpha 2mcg IV 10X1ml Ampoules Intravenous alfacalcidol vitamin D analogue (higher volume ampoule) for management of hypocalcemia, secondary hyperparathyroidism and osteodystrophy.
  • One Alpha 2mcg/mL 20ml Drops Oral drops formulation of alfacalcidol vitamin D analogue for hypocalcemia, secondary hyperparathyroidism and osteodystrophy.
  • Ridaura 3mg Capsules Auranofin antirheumatic agent for active rheumatoid arthritis.
  • Rivotril 0.5mg Tablets Clonazepam anticonvulsant for myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut Syndrome).
  • Rivotril 2mg Tablets Clonazepam anticonvulsant (higher strength) for myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut Syndrome).
  • Rythmodan 100mg Capsules Disopyramide antiarrhythmic agent for documented life-threatening ventricular arrhythmias.
  • Suprefact 6.3mg Depot Buserelin (Buserelin Acetate) LHRH analogue for hormone-dependent advanced carcinoma of the prostate gland (Stage D).
  • Suprefact 9.45mg Depot Buserelin (Buserelin Acetate) LHRH analogue (higher dose) for hormone-dependent advanced carcinoma of the prostate gland (Stage D).
  • Suprefact Injection 1mg/ml Buserelin (Buserelin Acetate) LHRH analogue injectable solution for hormone-dependent advanced prostate carcinoma.
  • Valcyte 450mg Tablets Valganciclovir antiviral agent for cytomegalovirus (CMV) retinitis.
  • Valcyte 50mg/ml Valganciclovir oral solution antiviral agent for cytomegalovirus (CMV) retinitis.
  • Vepesid 50mg Capsules Etoposide antineoplastic agent for small and non-small cell carcinoma of the lung, malignant lymphoma, and testicular malignancies.
  • Vesanoid 10mg Capsules Tretinoin differentiation inducing agent for acute promyelocytic leukemia.
  • Vimovo 375/20mg Tablets Combination of naproxen and esomeprazole NSAID with proton pump inhibitor for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
  • Vimovo 500/20mg Tablets Higher strength combination of naproxen and esomeprazole NSAID with proton pump inhibitor for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
  • Viskazide 10/50 Tablets Pindolol/hydrochlorothiazide antihypertensive combination agent for hypertension.
  • Viskazide 1025 Tablets Pindolol/hydrochlorothiazide antihypertensive combination agent (different ratio) for hypertension.
  • Visken 10mg Tablets Pindolol antihypertensive and antianginal agent for hypertension and angina pectoris.
  • Visken 5mg Tablets Pindolol antihypertensive and antianginal agent (lower strength) for hypertension and angina pectoris.
  • Visudyne 15mg Injection Verteporfin photosensitizing agent for classic subfoveal choroidal neovascularization in patients with age-related macular degeneration, pathologic myopia, and presumed ocular histoplasmosis.
  • Xenical 120mg Capsules Orlistat anti-obesity agent and gastrointestinal lipase inhibitor for obesity management, weight loss and weight maintenance.
  • Melinta Therapeutics Anti-Infective Portfolio (BAXDELA, KIMYRSA, ORBACTIV, VABOMERE) In-licensed portfolio of four novel anti-infective prescription products from Melinta Therapeutics (BAXDELA, KIMYRSA, ORBACTIV, VABOMERE) registered and commercialized by Xediton in Canada for pathogens on Canada's Pathogens of Interest List.
  • Valeo Pharma-Acquired Specialty Pharmaceutical Portfolio Specialty pharmaceutical portfolio in Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products, retained through the February 2025 acquisition of Valeo Pharma Inc. (including subsidiaries Valeo Pharma Corp. and VPI Pharmaceuticals Inc.).

Companies that use Xediton Pharmaceuticals

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Xediton Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Xediton Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Valeo Pharma Inc.coreStrategic or Co-development Partner · 4 February 2025Xediton completed a share purchase agreement to acquire 100% of Valeo Pharma Inc., which was under proceedings under the Companies' Creditors Arrangement Act (CCAA). The transaction was approved by the Quebec Superior Court on February 4, 2025. Xediton retained Valeo's existing licenses, operating permits, supply agreements, product listing agreements, intellectual property, and ownership of Valeo's subsidiaries (Valeo Pharma Corp. and VPI Pharmaceuticals Inc.).
  • Melinta TherapeuticscoreStrategic or Co-development Partner · 15 May 2023Exclusive commercialization and licensing agreement for four novel anti-infective products: BAXDELA (delafloxacin), KIMYRSA (oritavancin), ORBACTIV (oritavancin), and VABOMERE (meropenem and vaborbactam). Xediton is responsible for registration and commercialization of these products in Canada. These products have been approved by the US FDA and may be eligible for Priority Review by Health Canada.
  • Cheplapharm Arzneimittel GmbHcoreStrategic or Co-development PartnerLong-term international partnership for bringing pharmaceutical products to the Canadian market. Cheplapharm is a German pharmaceutical company with a focus on established medicines.
  • Sebela PharmaceuticalscoreStrategic or Co-development PartnerStrategic partnership with Sebela Pharmaceuticals for product licensing and commercialization in Canada. Sebela is a global pharmaceutical company.
  • Grunenthal GroupcoreStrategic or Co-development PartnerInternational partnership with Grunenthal Group, a German pharmaceutical company specializing in pain management and other therapeutic areas, to bring products to the Canadian market.
  • Quantum GenomicsminorStrategic or Co-development PartnerPartnership with Quantum Genomics, a biopharmaceutical company focused on cardiovascular and neurological diseases, for potential product introduction to Canadian market.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Xediton Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Duchesnay: Canadian specialty pharma focused on women's health, oncology, and rare diseases; comparable in-licensing and commercialization profile within the Canadian market.
  • Cipher Pharmaceuticals: Canadian specialty pharma that licenses, acquires, and commercializes niche and mature products across multiple therapeutic categories in Canada, sharing Xediton's lean commercialization approach and geographic concentration.
  • Knight Therapeutics: Montreal-based Canadian specialty pharmaceutical company with an in-licensing and commercialization model very similar to Xediton's, focused on acquiring and commercializing innovative and established products in Canada and select emerging markets.
  • HLS Therapeutics: Canadian specialty pharmaceutical company focused on acquiring and commercializing late-stage products, including established brands, in Canada — a direct analogue in both therapeutic strategy and Canadian-only footprint.
  • Searchlight Pharma: Canadian specialty pharma that in-licenses and commercializes branded prescription, OTC, and diagnostic products in Canada — a closely analogous in-licensing commercialization peer to Xediton.
  • Paladin Labs: Canadian specialty pharma (acquired by Endo) historically built on in-licensing niche and established products for the Canadian market — directly comparable business model to Xediton's pre-Valeo operations.

Others

  • Melinta Therapeutics: U.S. anti-infectives company that licensed four products (BAXDELA, KIMYRSA, ORBACTIV, VABOMERE) to Xediton for Canada; a direct partner and therefore a closely adjacent rather than competing entity.
  • Cheplapharm Arzneimittel GmbH: German specialty pharma specializing in established-brand lifecycles and a long-term Xediton partner; a useful upstream comparator for the mature-brand commercialization model Xediton runs in Canada.

Broad incumbents

  • Apotex: Canada's largest generic pharmaceutical manufacturer and distributor; competes with Xediton for the same Canadian wholesale channel and overlapping prescriber base, though Apotex is a manufacturer rather than a pure commercialization partner.
  • Bausch Health Companies: Large Canadian-headquartered specialty pharma with a broad therapeutic-area portfolio and established Canadian commercial infrastructure; overlaps with Xediton on the specialty/mature-brand strategy but at vastly greater scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Xediton Pharmaceuticals social profiles

Digital presence

Xediton Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xediton Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles1 record

Xediton Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Xediton Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xediton Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xediton Pharmaceuticals

What does Xediton Pharmaceuticals do?

Xediton licenses, acquires, and commercializes specialty pharmaceutical products—including prescription medications, medical devices, and OTC products—for the Canadian market. The company handles regulatory submissions to Health Canada, market access, and sales through wholesalers, hospitals, and a territory-based sales force, partnering with global pharmaceutical companies to bring established and innovative drugs to Canadian patients.

Is Xediton Pharmaceuticals a public or private company?

Xediton Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Xediton Pharmaceuticals founded?

Xediton Pharmaceuticals was founded in 2007. It employs 1 to 10 people.

Where is Xediton Pharmaceuticals based?

Xediton Pharmaceuticals is headquartered in Oakville, Canada, in the North America region.

How does Xediton Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Commercialization Rights.

Who are Xediton Pharmaceuticals's main competitors?

Direct peers on record are Duchesnay, Cipher Pharmaceuticals, Knight Therapeutics, HLS Therapeutics, Searchlight Pharma and Paladin Labs. Others are Melinta Therapeutics and Cheplapharm Arzneimittel GmbH. Broad incumbents are Apotex and Bausch Health Companies.

Does Xediton Pharmaceuticals have an API?

No public API is recorded for Xediton Pharmaceuticals.

What industry is Xediton Pharmaceuticals in?

Xediton Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooValeo Pharma announces the closing of a share purchase agreement with Xediton Pharmaceuticals Inc.Valeo Pharma Inc. completed a share purchase agreement with Xediton Pharmaceuticals Inc. as part of its proceedings under the Companies' Creditors Arrangement Act. The transaction involved the acquisition of 100% of Valeo by Xediton, including its licenses, agreements, and subsidiaries, but with no recovery for previous shareholders.XeditonXediton Pharmaceuticals Inc. announces a share purchase agreement with Valeo PharmaXediton Pharmaceuticals Inc. has completed the acquisition of 100% of Valeo Pharma Inc.'s outstanding shares through a court-approved transaction on February 4, 2025, marking the conclusion of Valeo's Companies' Creditors Arrangement Act (CCAA) proceedings. The Quebec Superior Court granted approval via a vesting order, with Ernst & Young Inc. serving as the court-appointed monitor that conducted the sale and investor solicitation process. Existing Valeo shareholders are not expected to receive any recovery, and Xediton has committed to retaining Valeo's licenses, supply agreements, intellectual property, subsidiaries, and workforce to continue commercial operations.GlobeNewswireQuantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton PharmaceuticalsQuantum Genomics and Xediton Pharmaceuticals signed an exclusive licensing agreement to develop and commercialize firibastat for resistant hypertension in Canada. Quantum Genomics will receive up to $11.35 million in upfront and milestone payments plus double-digit royalties. The company has already recruited patients for the pivotal phase III study FRESH.YahooQuantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton PharmaceuticalsQuantum Genomics and Xediton Pharmaceuticals signed an exclusive licensing agreement to develop and commercialize firibastat for resistant hypertension in Canada. Quantum Genomics will receive up to $11.35 million in upfront and milestone payments plus royalties. The target population is estimated at 1-1.5 million patients.GlobeNewswireBiohit signs distribution agreement with XeditonBiohit signed a distribution agreement with Canadian Xediton Pharmaceuticals to distribute its Acetium product in Canada. Acetium binds carcinogenic acetaldehyde and targets anacidic stomachs, a risk factor for stomach and esophageal cancer. Xediton holds exclusive rights to market the product in Canada.